Midazolam
- Generic Name
- Midazolam
- Brand Names
- Buccolam, Busulfex, Nayzilam, Seizalam
- Drug Type
- Small Molecule
- Chemical Formula
- C18H13ClFN3
- CAS Number
- 59467-70-8
- Unique Ingredient Identifier
- R60L0SM5BC
- Background
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...
- Indication
Midazolam has different indications depending on its formulation by the FDA.
Nasal
...
- Associated Conditions
- Epileptic seizure, Status Epilepticus
- Associated Therapies
- Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
Combined Ketamine and Midazolam for Generalized Convulsive Status Epilepticus
- Conditions
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 144
- Registration Number
- NCT05779657
- Locations
- 🇪🇬
Sohag University Hospital, Sohag, Egypt
Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT05760261
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Sedative Effect and Safety of Remimazolam Besylate in ARDS Patients
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Zhiming Jiang
- Target Recruit Count
- 100
- Registration Number
- NCT05758597
- Locations
- 🇨🇳
Department of Intensive Care Medicine, Jinan, Shandong, China
A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT05741385
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 67
- Registration Number
- NCT05738291
- Locations
- 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands
Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 80
- Registration Number
- NCT05736341
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Enhancing Week-long Psychological Treatment for PTSD With Ketamine
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Yale University
- Target Recruit Count
- 162
- Registration Number
- NCT05737693
- Locations
- 🇮🇱
Tel Aviv University, Tel Aviv, Israel
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
A Study of Milvexian in Healthy Adult Females
- Conditions
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 20
- Registration Number
- NCT05706753
- Locations
- 🇧🇪
SGS Belgium NV, Edegem, Belgium
Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05694533
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 1000
- Registration Number
- NCT05681572
- Locations
- 🇫🇷
Uhmontpellier, Montpellier, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.